-- Mary Elizabeth Dallas
THURSDAY, Feb. 14 (HealthDay News) -- Chemotherapy can be a
lifesaver for thousands of cancer patients, but a new study
suggests that it might slightly raise the odds for a type of
leukemia later in life.
Over the past 30 years, the risk for acute myeloid leukemia
(AML) has increased for patients who underwent chemotherapy for
certain forms of cancer, particularly non-Hodgkin lymphoma, the new
On the other hand, the researchers from the U.S. National Cancer
Institute said other cancer survivors may have a reduced risk for
AML due to a change in chemotherapy agents that occurred decades
One expert not connected to the study stressed that cancer
patients need to put the findings into perspective.
"It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," said Dr. Jonathan Kolitz, chief of hematologic oncology at the North Shore-LIJ Cancer Institute in Lake Success, N.Y.
The study was published online Feb. 14 in the journal
The findings aren't a big surprise to oncologists.
"It has long been known that some types of chemotherapy are associated with a high risk of developing subsequent leukemia," explained study lead author Lindsay Morton, in NCI's Radiation Epidemiology Branch in the Division of Cancer Epidemiology and Genetics, in an NCI news release. "The goal of this study was to better understand how cancer patients' risk of developing leukemia has changed over time."
In conducting the study, the researchers assessed the risk for
leukemia of more than 426,000 adults who received chemotherapy for
cancer diagnosed between 1975 and 2008. Of these patients, 801 went
on to develop AML.
Patients who survived non-Hodgkin lymphoma were at greater risk
for AML, the team found. According to the researchers, that may be
due to prolonged survival for forms of the disease that require
multiple courses of chemotherapy.
Since 2000, patients treated for esophageal, prostate and
cervical cancer were also found to be at greater risk for AML, the
researchers say. The study also showed that those treated for
cancer since the 1990s for cancers of the bones and joints, as well
as the endometrium (uterine lining), are also at increased risk for
Meanwhile, patients treated for ovarian cancer, myeloma, and
possibly lung cancer may be at reduced risk for AML. The
researchers suggested the lower risk among patients with these
forms of cancer may be linked to a treatment switch that occurred
in the early 1980s from an agent called melphalan to newer,
More research is needed to determine the risks associated with
various chemotherapy agents, the researchers said.
For his part, Kolitz said that it is "gratifying to see that the
likelihood of developing leukemia from the treatment of several of
the studied cancers actually fell over the last decade, very likely
because of decreased use of drugs that are most potently [linked to
Another expert agreed that the overall risk to any one cancer
patient is small.
"This study confirms that a very small number of patients may be at risk for the development of a second cancer due to the effects of chemotherapy," said Dr. William Carroll, a pediatric oncologist at NYU Langone Medical Center, in New York City.
"Patients should always ask their doctor about the risk of serious side effects associated with particular parts of therapy, and whether agents with fewer side effects can be substituted without compromising the best chance for cure," said Carroll, who is also director of the NYU Cancer Institute and a professor at the NYU School of Medicine.
"Finally," he added, "it is increasingly clear that certain patients may be more likely to experience certain side effects based on their own genetic makeup. The ability to determine who is at greatest risk [via genetic testing], thereby allowing therapy to be tapered is one of the fundamental goals of personalized medicine."
The U.S. National Cancer Institute provides more information on
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.